OPKO Health (NASDAQ:OPK) Announces Earnings Results

OPKO Health (NASDAQ:OPK) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.07) EPS for the quarter, hitting analysts’ consensus estimates of ($0.07), FiscalAI reports. The company had revenue of $130.83 million for the quarter, compared to analyst estimates of $136.62 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%. The business’s revenue was down 56.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.03 earnings per share.

Here are the key takeaways from OPKO Health’s conference call:

• OPKO agreed to sell substantially all of BioReference’s remaining operations to Labcorp for about $722 million in cash, with potential 4Kscore royalties of up to $150 million over 10 years. The deal, which remains subject to customary closing conditions, would complete OPKO’s exit from diagnostics and refocus it on biotech and global products.
• Continuing-operations revenue rose 16% to $65.4 million year over year, led by OPKO Iberoamerica, RAYALDEE and mazdutide royalties. Global products reported $6 million of operating income, versus a $1.2 million loss a year earlier.
• Pipeline programs advanced, including completion of enrollment in the planned phase I cohorts for MDX-2301, with management describing its blinded safety profile as favorable. OPKO is preparing subcutaneous dosing studies for several ModeX candidates, while its first in vivo CAR-T program is now targeted for first-in-human studies in mid-2027, later than previously planned.
• Innovative biotech’s operating loss widened to $26.8 million from $22.5 million, as increased research and development activity raised costs. OPKO expects about $125 million in BioReference sale-related costs, and forecast a roughly $40 million loss from discontinued operations in Q4.
• OPKO ended the quarter with $403.2 million in cash, cash equivalents and restricted cash, and repurchased 7.2 million shares for $10.6 million. It withdrew consolidated full-year guidance and issued continuing-operations revenue guidance of $268 million–$278 million; management said it would provide more detail on capital allocation as the Labcorp closing approaches.

OPKO Health Trading Down 4.2%

NASDAQ:OPK traded down $0.07 during trading hours on Thursday, hitting $1.70. 5,720,875 shares of the stock were exchanged, compared to its average volume of 3,224,547. The company has a market capitalization of $1.27 billion, a P/E ratio of -18.83 and a beta of 1.52. The company has a quick ratio of 2.93, a current ratio of 3.35 and a debt-to-equity ratio of 0.28. The company’s 50 day moving average is $1.58 and its two-hundred day moving average is $1.35. OPKO Health has a twelve month low of $0.98 and a twelve month high of $1.83.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Zacks Research raised OPKO Health from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. UBS Group set a $4.00 price target on shares of OPKO Health in a research report on Friday, October 16th. Barrington Research raised shares of OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 price objective on the stock in a report on Friday, October 16th. Piper Sandler restated an “overweight” rating and issued a $4.00 price objective (up from $3.00) on shares of OPKO Health in a research report on Friday, October 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, OPKO Health currently has an average rating of “Moderate Buy” and an average price target of $3.42.

Key Headlines Impacting OPKO Health

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO agreed to sell substantially all remaining BioReference diagnostic operations to Labcorp for $722 million in cash. The proceeds could strengthen its balance sheet as it narrows its focus to biotechnology. OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
• Neutral Sentiment: The company forecast $268 million to $278 million in 2026 continuing-operations revenue following the asset sale. OPKO reported a quarterly loss of $0.05 per share, narrower than the $0.07 loss analysts expected, according to Zacks. OPKO 2026 continuing-operations revenue outlook
• Negative Sentiment: Continuing-operations revenue was reported at $65.4 million, well below the $136.6 million FactSet estimate. Reports also cited widening biotech losses and a delayed CAR-T timeline, raising concerns about execution and the path to growth despite the sale proceeds. OPKO Q3 2026 earnings call highlights

About OPKO Health

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.